Market news

Detailed price information for Fair Isaac and Company (FICO-N) from The Globe and Mail including charting and trades.

Geron (NASDAQ:GERN) executives said the company remains on track to generate 2026 RYTELO net revenue of $220 million to $240 million, with Chief Executive Officer Harout Semerjian saying the company now expects results toward the midpoint to high end of that range, or approximately $230 million to $

Geron (NASDAQ:GERN) said it expects full-year net revenue from RYTELO to land in the mid-to-high end of its previously stated range, or approximately $230 million to $240 million, as the company continues to expand use of the telomerase inhibitor in lower-risk myelodysplastic syndromes, or MDS. Dur

FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a hematology-focused biopharmaceutical company pursuing more meaningful moments for people living with blood cancer, today announced that members of the management team are scheduled to participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference:Fireside Chat on Wednesday, September 9, 2026, at 8:00 a.m. ET in New York, NY H.C. Wainwright 28th Annual Global Investmen

FOSTER CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective August 17, 2026, it granted stock options to purchase an aggregate of 311,250 shares of common stock to six newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.53 per share, which is equal to the closing price of Geron’s common stock o

Detailed price information for Geron Corp (GERN-Q) from The Globe and Mail including charting and trades.

Detailed price information for Azenta Inc (AZTA-Q) from The Globe and Mail including charting and trades.

RYTELO demand grew 5% as prescribing accounts hit 1,575 since launch.

Geron Corp (GERN) reports 17% year-over-year net revenue growth, raises full-year guidance, and progresses regulatory discussions for its IMPACT MF trial.

Moby summary of Geron Corporation's Q2 2026 earnings call

Geron (NASDAQ:GERN) reported second-quarter net revenue of $57.5 million, up 17% from a year earlier and 11% sequentially, as the company continued to expand use of RYTELO among patients with lower-risk myelodysplastic syndromes, or MDS. Chief Executive Officer Harout Semerjian said first-half net

Geron (GERN) delivered earnings and revenue surprises of -100.00% and +4.49%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Achieved $57.5 million in RYTELO® (imetelstat) net product revenue in Q2 2026, an increase of 11% compared to Q1 2026 Reiterated 2026 RYTELO net product revenue and total operating expenses expected to be in the ranges of $220 million to $240 million, and $230 million to $240 million, respectively Ended Q2 2026 with cash, cash equivalents, restricted cash and marketable securities of $327 million Broadened leadership team with the appointment of Chinmaya Rath as Chief Business Officer Company to

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webc

FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees’ acceptance of employment with Geron. The stock options have an exercise price of $1.44 per share, which is equal to the closing price of Geron’s common stock on

FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron’s new Chief Business Officer, as an inducement material to his acceptance of employment with Geron. The stock option was granted on July 13, 2026. The stock option has an exercise price of $1.42 per share, which i

Geron Corporation (NASDAQ:GERN) is one of the 10 Fastest Growing Tech Penny Stocks to Buy. On June 18, 2026, Geron Corporation (NASDAQ:GERN) reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees. The grants were made as an inducement material […]

Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companiesFOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the appointment of Chinmaya Rath as Chief Business Officer. “Chinmaya is an experienced business development leader who will bring strategic insights and further executional